To evaluate whether zurletrectinib increased brain penetration also translated into improved activity against brain tumors compared to the other next-generation agents, we tested the in vivo activity of zurletrectinib in mouse glioma orthotopic xenografts harboring the Trka G598R or the Trka G598R/G670A mutation. The gene discussed is NTRK1; the disease is central nervous system cancer.